U.S. Markets closed

CombiMatrix Corporation (CBMX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
5.50+0.05 (+0.92%)
At close: 4:00PM EDT
People also watch
  • Beware of GreatDayIsBack2017. He's a boiler room scammer. Whatever scam stock he pumps, will implode.
  • What's crapppppier CBMX or OMER or RAD? Too close to call?
  • From $2,238.00 to $6.35. Is there a crappppppppppier stock?
    When do they close up shop? After another reverse split?
  • Q2/ 2017 vs Q2/2016.
    Revenue in Q2/2016 was 3.107M. Looks like they'll do $4.0M in 2017 - that's a 30% increase which is what they have been doing for a while.
    But gross profit was 54% last year. They are running closer to 60% this year. That will make a big difference.
    They lost $1.24M last year. Running the figures for 2017, I see where they will lose $350K this year or roughly 12 cents/share.

    Anyone else got figures?
  • Blowout!!! Beat by .07 and beat on revenues! This is finally going to return to above $10 where I will at least break even! Then I'll hold for profits. Very glad us long suffering longs are about to see vindication! Great job management!!!!!!!!!!!!
  • Timber... Might buy at $5.20...
  • Still trading at 36 cents before 15 to 1 Reverse Split... Quite the Volume today, 1 million shares traded with about 3 million shares outstanding...
    AQSZF (MC $11 M) is close to profitability and to file 3 NDA and the whole company is valued at ridiculous $11 Million ,this unknown stock is definitely one of the cheapest Biotech in the sector .Stock should be at minimum $2+ right now .

    Market Cap :US$ 11 Million
    Cash $4.1 Million << enough untill mid 2018
    Price 0.18



    Operational profitability estimated in 2017

    File for CDN approval of Topiramate XR in 1H 2017

    File for CDN approval of Oxcarbazepine XR in 1H 2017

    Additional Product Deals in 2017

    Partnership for AQS1301 in 2017

    Two products launches to date (Tacrolimus IR and Vistitan™)

    3 long-acting, transdermal programs in development, on track to file NDA in 2018

    Aequus Pharmaceuticals
    Aequus has an expanding product pipeline of drugs in Canada. Revenues and cash flows are increasing and products produce a 50% margin, Edward Karr, Managing ...
  • Where will this go tomorrow based on latest financial information?
  • Debating to add a position here, local Orange County, CA investor... Albeit, CBMX has had about 3 Reverse Splits, so not a lot of confidence there... Is this the turning point with a loss under $500K vs. over $1.5 million last year... Cash Flow positive goal in Q4 2017???????? Only 2.9 million shares outstanding... Roll the dice here????????????????????
  • Earning release May 4.
    I'm looking for $3.85M in revenue; $4.1 in total expenses for a loss of 250K. With 2.5M shares outstanding, that would be a loss of 10 cents per share.
    I would sure love to see more revenue, though, which of course would mean more of everything else but loss.
  • What would y'all say to someone who currently holds CBMX currently. Sell? Hold?
  • Last night I dreamed I ate a ten-pound marshmallow, and when I woke up the pillow was gone. http://dataunion.tistory.com/1424

    [2016-MAY] CombiMatrix Corporation NASDAQ : CBMX Correlation Histogram
    X axis : Stocks Price Correlation Coefficient Y axis : Quantity of stocks May-2016 1,000 Day Parameter 2,830 NASDAQ Stocks Price Analysis This stock mode of correlation coefficient is -0.8 In other words, the correlation coefficient of the other stoc
  • You guys are missing one VERY KEY point: When SQNM was purchased their volumes went elsewhere. So the unit volume growth you're looking at is not apples to apples. Unit growth is actually much higher than they're reporting because prior year includes SQNM business.

    Also, anyone can do testing. Anyone can do banking. Anyone can do security software. Anyone can do homes. I can name plenty of smaller players in those industries executing extremely well against BAC, TOL, etc.
  • Is any part of the company's microarray technology proprietary? What prevents any test lab from buying microarray technology and competing directly against CBMX at a lower price?
  • Did anyone else notice page 22 of the 10K, which reports about the Series F warrants? If I am reading this correctly, the Series F warrants contain provisions that dilute out common shareholders in the event of a buyout. Common shareholders will in effect only receive 70% of the consideration in the event of a takeover offer.

    This alone may explain why the stock has been undervalued here.
  • Keep kicking the tires here! Hard to get my arms around the upside potential... One negative is the most recent Reverse Split, which spells concern about the management ability to execute... Albeit, small market cap, many here in S. California could right a check for the current market cap... Another negative is NO reputable analyst coverage....
  • Bashers showing up and the price is skyrocketing? We could be on the precipice of something huge!
  • Does anyone have data on what the unit growth was in microarray testing for the reproductive conditions that CBMX tests, looking at growth from 2015 to 2016 specifically?

    Regarding pricing: CBMX unit volume is up about 10% YOY on their 10K, while the sales is up 27%. This suggests pricing power, and that is quite confusing given that the equipment is generic. How are they able to increase prices and not have that competed away?
  • Why the move higher?